Melioidosis

Current Opinion in Infectious Diseases

Volumn 19, Issue 5, 2006, Pages 421-428

  Peacock, Sharon J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Burkholderia pseudomallei; Melioidosis; Review

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CEFTAZIDIME; CHLORAMPHENICOL; COTRIMOXAZOLE; DOXYCYCLINE; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM;

ANTIMICROBIAL THERAPY; BACTERIAL IMMUNITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; GENOMICS; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; MELIOIDOSIS; MORTALITY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SERODIAGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; GENOMICS; HUMANS; MELIOIDOSIS; TREATMENT OUTCOME;

EID: 33748343781     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000244046.31135.b3     Document Type: Review

References (70)

1. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18:383-416. An excellent, detailed review of the topic.
2. Rolim DB.Melioidosis, northeastern Brazil. Emerg Infect Dis 2005; 11:1458-1460. This paper describes the investigation of the recent emergence of melioidosis in Brazil.
3. Cheng AC, Jacups SP, Gal D, et al. Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int J Epidemiol 2006; 35:323-329.
4. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005; 43:970-972. An incubation period of 62 years between exposure to B. pseudomallei and the development of clinical manifestations of infection is the longest on record, and demonstrates an extraordinary ability to evade the host immune response.
5. Athan E, Allworth AM, Engler C, et al. Melioidosis in tsunami survivors. Emerg Infect Dis 2005; 11:1638-1639. This study reports the occurrence of melioidosis in four individuals with post-immersion pneumonia associated with the tsunami in Indonesia.
6. Chierakul W, Winothai W, Wattanawaitunechai C, et al. Melioidosis in 6 tsunami survivors in southern Thailand. Clin Infect Dis 2005; 41:982-990. This report of six cases of melioidosis in tsunami survivors in Thailand highlights the risk of infection in survivors.
7. Wuthiekanun V, Chierakul W, Rattanalertnavee J, et al. Serological evidence for increased human exposure to Burkholderia pseudomallei following the tsunami in southern Thailand. J Clin Microbiol 2006; 44:239-240. Serological testing of individuals soon after the tsunami and 4 months later suggests that uninjured bystanders were also exposed to B. pseudomallei.
8. Chierakul W, Wuthiekanun V, Chaowagul W, et al. Disease severity and outcome of melioidosis in HIV coinfected individuals. Am J Trop Med Hyg 2005; 73:1165-1166. Despite profound changes in immune status, individuals infected with HIV do not appear to do worse during melioidosis than those who are not HIV positive. Somewhat counterintuitively, HIV does not appear to be a risk factor for melioidosis.
9. Wuthiekanun V, Desakorn V, Wongsuvan G, et al. Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol 2005; 12:555-556. A technique is described that allows the presumptive identification of B. pseudomallei from clinical specimens within 10 min.
10. Cheng AC, Wuthiekanun V, Limmathurosakul D, et al., The role of selective and nonselective media for the isolation of Burkholderia pseudomallei from throat swabs in patients with melioidosis J Clin Microbiol (in press).
11. Peacock SJ, Chieng G, Cheng AC, et al. Comparison of Ashdown's medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol 2005; 43:5359-5361. This study provides evidence for the use of B. cepacia medium for the isolation of B. pseudomallei from clinical specimens. This may prove useful in non-endemic areas where Ashdown's medium may not be available.
12. Glass MB, Popovic T. Preliminary evaluation of the API 20NE and RapID NF plus systems for rapid identification of Burkholderia pseudomallei and B. mallei. J Clin Microbiol 2005; 43:479-483.
13. Inglis TJ, Merritt A, Chidlow G, et al. Comparison of diagnostic laboratory methods for identification of Burkholderia pseudomallei. J Clin Microbiol 2005; 43:2201-2206.
14. Dance DA, Wuthiekanun V, Naigowit P, White NJ. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol 1989; 42:645-648.
15. Lowe P, Haswell H, Lewis K. Use of various common isolation media to evaluate the new VITEK 2 colorimetric GN card for identification of Burkholderia pseudomallei. J Clin Microbiol 2006; 44:854-856.
16. Wuthiekanun V, Cheng AC, Chierakul W, et al. Trimethoprim/ sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother 2005; 55:1029-1031. A useful reminder that disk susceptibility testing grossly overestimates B. pseudomallei resistance to TMP-SMX. The finding that 13% of B. pseudomallei are TMP-SMX resistant in northeast Thailand is worrying given the widespread use of this drug during oral eradication therapy, although rates do not appear to be increasing over time.
17. Gal D, Mayo M, Spencer E, et al. Application of a polymerase chain reaction to detect Burkholderia pseudomallei in clinical specimens from patients with suspected melioidosis. Am J Trop Med Hyg 2005; 73:1162-1164. This represents the first published evaluation of the utility of PCR for the diagnosis of melioidosis.
18. Novak RT, Glass MB, Gee JE, et al. Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei. J Clin Microbiol 2006; 44:85-90.
19. Tomaso H, Pitt TL, Landt O, et al. Rapid presumptive identification of Burkholderia pseudomallei with real-time PCR assays using fluorescent hybridization probes. Mol Cell Probes 2005; 19:9-20.
20. Thibault FM, Valade E, Vidal DR. Identification and discrimination of Burkholderia pseudomallei, B. mallei, and B. thailandensis by real-time PCR targeting type III secretion system genes. J Clin Microbiol 2004; 42:5871-5874.
21. U'Ren JM, Van Ert MN, Schupp JM, et al. Use of a real-time PCR TaqMan assay for rapid identification and differentiation of Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 2005; 43:5771-5774.
22. Lee MA, Wang D, Yap EH. Detection and differentiation of Burkholderia pseudomallei, Burkholderia mallei and Burkholderia thailandensis by multiplex PCR. FEMS Immunol Med Microbiol 2005; 43:413-417.
23. Cheng AC, Peacock SJ, Limmathurotsakul D, et al. Prospective evaluation of a rapid immunochromogenic cassette test for the diagnosis of melioidosis in northeast Thailand. Trans R Soc Trop Med Hyg 2006; 100:64-67.
24. Chuah SC, Gilmore G, Norton RE. Rapid serological diagnosis of melioidosis: an evaluation of a prototype immunochromatographic test. Pathology 2005; 37:169-171.
25. Cheng AC, O'Brien M, Freeman K, et al. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg 2006; 74:330-334. This paper demonstrates that the indirect haemagglutination assay is not useful for either the diagnosis of melioidosis or the evaluation of response to therapy in this endemic setting.
26. Chierakul W, Anunnatsiri S, Short JM, et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 2005; 41:1105-1113. In-hospital mortality was equivalent for these two-drug regimens for the initial treatment of severe melioidosis.
27. Chaowagul W, Chierakul W, Simpson AJ, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005; 49:4020-4025. Oral eradication therapy for melioidosis can now be reduced from four drugs to three drugs on the basis of this study, which showed equivalence between the two regimens as defined by culture-confirmed recurrence. This may contribute towards improved tolerance and patient compliance.
28. Wuthiekanun V, Peacock SJ. Management of melioidosis, Expert Rev Anti Infect Ther (in press).
29. Cheng AC, Stephens DP, Anstey NM, Currie BL. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:32-37.
30. Currie B. Combination antimicrobial therapy for severe melioidosis. Australian Society for Antimicrobials Newsletter 2005; 23:16.
31. Cheng AC, Jacups SP, Anstey NM, Currie BJ. A proposed scoring system for predicting mortality in melioidosis. Trans R Soc Trop Med Hyg 2003; 97:577-581.
32. Limmathurotsakul D, Wuthiekanun V, Chierakul W, et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J Clin Microbiol 2005; 43:2274-2276. Defining the presence and colony count of B. pseudomallei in the urine of patients with melioidosis gives an indicator of outcome.
33. Huis in't Veld D, Wuthiekanun V, Cheng AC, et al. The role and significance of sputum cultures in the diagnosis of melioidosis. Am J Trop Med Hyg 2005; 73:657-661. Melioidosis patients with sputum culture positive for B. pseudomallei are more likely to die than those with sputum culture negative for B. pseudomallei.
34. LaRosa SP, Opal SM, Utterback B, et al. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10:25-31.
35. Maharjan B, Chantratita N, Vesaratchavest M, et al. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J Clin Microbiol 2005; 43:6032-6034. Genotyping of isolate pairs from primary infection and recurrent disease showed that 25% of cases may have been caused by re-infection with a new bacterial strain.
36. Anuntagool N, Wuthiekanun V, White NJ, et al. Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. Am J Trop Med Hyg 2006; 74:348-352.
37. Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 2004; 101:14240-14245.
38. Ou K, Ong C, Koh SY, et al. Integrative genomic, transcriptional, and proteomic diversity in natural isolates of the human pathogen Burkholderia pseudomallei. J Bacteriol 2005; 187:4276-4285.
39. Duangsonk K, Gal D, Mayo M, et al. Use of a variable amplicon typing scheme reveals considerable variation in the accessory genomes of isolates of Burkholderia pseudomallei. J Clin Microbiol 2006; 44:1323-1334. This technique clustered bacterial isolates into groups, one of which was mostly isolated with severe melioidosis. This has led to the suggestion that the content of the accessory genome may play a role in determining clinical manifestations of disease.
40. Cheng AC, Godoy D, Mayo M, et al. Isolates of Burkholderia pseudomallei from northern Australia are distinct by multilocus sequence typing, but strain types do not correlate with clinical presentation. J Clin Microbiol 2004; 42:5477-5483.
41. Vesaratchavest M, Tumapa S, Day NP, et al. Nonrandom distribution of Burkholderia pseudomallei clones relating to geographical location and virulence, J Clin Microbiol (in press).
42. Haque A, Easton A, Smith D, et al. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J Infect Dis 2006; 193:370-379. This paper reported that the T-cell response to B. pseudomallei infection in mice is biphasic, with an early cytokine-induced phase in which T cells appear to be redundant for initial bacterial clearance, followed by a later antigen-induced phase in which B. pseudomallei-specific T cells, in particular CD4 T cells, were important for host resistance.
43. Chen YS, Hsiao YS, Lin HH, et al. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 2006; 24:750-758.
44. Chen YS, Hsiao YS, Lin HH, et al. CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun 2006; 74:1699-1705.
45. Nelson M, Prior JL, Lever MS, et al. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 2004; 53:1177-1182.
46. Healey GD, Elvin SJ, Morton M, Williamson ED. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect Immun 2005; 73:5945-5951.
47. Elvin SJ, Healey GD, Westwood A, et al. Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun 2006; 74:1706-1711.
48. Ulett GC, Labrooy JT, Currie BJ, et al. A model of immunity to Burkholderia pseudomallei: unique responses following immunization and acute lethal infection. Microbes Infect 2005; 7:1263-1275. The observation that different strains of B. pseudomallei were associated with variable levels of protective immunity in an animal model could provide insights that may have application during vaccine development.
49. Song Y, Xie C, Ong YM, et al. The BpsIR quorum-sensing system of Burkholderia pseudomallei. J Bacteriol 2005; 187:785-790.
50. Valade E, Thibault FM, Gauthier YP, et al. The PmlI-PmlR quorum-sensing system in Burkholderia pseudomallei plays a key role in virulence and modulates production of the MprA protease. J Bacteriol 2004; 186:2288-2294.
51. Korbsrisate S, Vanaporn M, Kerdsuk P, et al. The Burkholderia pseudomallei RpoE (AlgU) operon is involved in environmental stress tolerance and biofilm formation. FEMS Microbiol Lett 2005; 252:243-249.
52. Subsin B, Thomas MS, Katzenmeier G, et al. Role of the stationary growth phase sigma factor RpoS of Burkholderia pseudomallei in response to physiological stress conditions. J Bacteriol 2003; 185:7008-7014.
53. Utaisincharoen P, Arjcharoen S, Limposuwan K, et al. Burkholderia pseudomallei RpoS regulates multinucleated giant cell formation and inducible nitric oxide synthase expression in mouse macrophage cell line (RAW 264.7) Microb Pathog 2006; 40:184-189.
54. Tuanyok A, Kim HS, Nierman WC, et al. Genome-wide expression analysis of iron regulation in Burkholderia pseudomallei and Burkholderia mallei using DNA microarrays. FEMS Microbiol Lett 2005; 252:327-335.
55. Alice AF, Lopez CS, Lowe CA, et al. Genetic and transcriptional analysis of the siderophore malleobactin biosynthesis and transport genes in the human pathogen Burkholderia pseudomallei K96243. J Bacteriol 2006; 188:1551-1566.
56. Taweechaisupapong S, Kaewpa C, Arunyanart C, et al. Virulence of Burkholderia pseudomallei does not correlate with biofilm formation. Microb Pathog 2005; 39:77-85.
57. Reckseidler-Zenteno SL, DeVinney R, Woods DE. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun 2005; 73:1106-1115.
58. Moore RA, Reckseidler-Zenteno S, Kim H, et al. Contribution of gene loss to the pathogenic evolution of Burkholderia pseudomallei and Burkholderia mallei. Infect Immun 2004; 72:4172-4187.
59. Stevens MP, Wood MW, Taylor LA, et al. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 2002; 46:649-659.
60. Breitbach K, Rottner K, Klocke S, et al. Actin-based motility of Burkholderia pseudomallei involves the Arp 2/3 complex, but not N-WASP and Ena/VASP proteins. Cell Microbiol 2003; 5:385-393.
61. Kespichayawattana W, Intachote P, Utaisincharoen P, Sirisinha S. Virulent Burkholderia pseudomallei is more efficient than avirulent Burkholderia thailandensis in invasion of and adherence to cultured human epithelial cells. Microb Pathog 2004; 36:287-292.
62. Essex-Lopresti AE, Boddey JA, Thomas R, et al. A type IV pilin, PilA, contributes to adherence of Burkholderia pseudomallei and virulence in vivo. Infect Immun 2005; 73:1260-1264.
63. Utaisincharoen P, Arjcharoen S, Lengwehasatit I, et al. Burkholderia pseudomallei invasion and activation of epithelial cells requires activation of p38 mitogen-activated protein kinase. Microb Pathog 2005; 38:107-112.
64. Nathan SA, Qvist R, Puthucheary SD. Kinetic studies of bioactive products nitric oxide and 8-iso-PGF(2alpha) in Burkholderia pseudomallei infected human macrophages, and their role in the intracellular survival of these organisms. FEMS Immunol Med Microbiol 2005; 43:177-183.
65. Ekchariyawat P, Pudla S, Limposuwan K, et al. Burkholderia pseudomallei-induced expression of suppressor of cytokine signaling 3 and cytokine-inducible src homology 2-containing protein in mouse macrophages: a possible mechanism for suppression of the response to gamma interferon stimulation. Infect Immun 2005; 73:7332-7339.
66. Suparak S, Kespichayawattana W, Haque A, et al. Multinucleated giant cell formation and apoptosis in infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB. J Bacteriol 2005; 187:6556-6560.
67. Warawa J, Woods DE. Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol Lett 2005; 242:101-108.
68. Stevens MP, Haque A, Atkins T, et al. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 2004; 150:2669-2676.
69. Zhang L, Wang Y, Picking WL, et al. Solution structure of monomeric BsaL, the type III secretion needle protein of Burkholderia pseudomallei. J Mol Biol 2006; 359:322-330.
70. Sun GW, Lu J, Pervaiz S, et al. Caspase-1 dependent macrophage death induced by Burkholderia pseudomallei. Cell Microbiol 2005; 7:1447-1458.